



Curriculum Vitae

Personal information

First name(s) / Surname(s) **Eva Regina Haspinger**
E-mail evaregina.haspinger@sabes.it

Title of qualification awarded Medical Oncologist

July 2018 – ongoing
Occupation or position held Azienda Sanitaria dell'Alto Adige – Ospedale di Merano (Prof M Mitterer)
Deputy Director, Consultant in Medical Oncology

January 2016 – July 2018
Occupation or position held Azienda Sanitaria dell'Alto Adige – Ospedale di Merano (Prof M Mitterer)
Consultant in Medical Oncology

November 2014 – December 2015
Occupation or position held Gustave Roussy, Villejuif cedex, Paris (Prof. JC Soria)
Consultant locum/researcher in Medical Oncology

August 2011 – October 2014
Occupation or position held Istituto Nazionale dei Tumori, Milano (Prof F de Braud)
Consultant locum/researcher in Medical Oncology

January 2010 – November 2010
Occupation or position held Temple University, Philadelphia (PA) (Prof. E Surmacz)
Researcher in glioblastoma and breast cancer

March 2008 – September 2011
Occupation or position held University of Verona – Italy (Prof. GL Cetto, Prof. GP Tortora)
Trainee in Medical Oncologist

July 2007 – March 2008
Occupation or position held Regional Hospital Bozen (Dr. C Graiff)
Medical Doctor

Education and training

October 2015 DUERTECC – Diplome universitaire Europeen de Recherche translationnelle et Clinique en Cancerologie
– Gustave Roussy

June 2015 DUCC – Diplome universitaire de Carcinologie Clinique – Universite Paris Sud XI

June 2012 Participation at Flims Workshop (Switzerland): Methods in Clinical Cancer Research (Phase II trial of intrapleural administration of Catumaxomab after first line chemotherapy with Cisplatin and Pemetrexed in patients with malignant pleural mesothelioma).

March 2012 Specialty in Medical Oncology at University of Verona (Thesis: Induction chemotherapy in patients with NSCLC Stage IIIA-IIIB. Clinical and pathological response based on molecular characteristics of primary tumour).

July 2007 Subscription to National Medical Order

March 2007 Degree in Medicine and Surgery at the University of Innsbruck – Austria (Thesis: Combination of radiotherapy and chemotherapy in patients with cervix uterine tumour).

July 2000 High school degree at scientific Lyceum, Bolzano – Italy



Curriculum Vitae

Organisational Skills and competences

- 2011 – 2015 Co – Principal Investigator in several clinical trials with special interest in lung cancer, timoma and mesothelioma; phase I trials
- September 2014 ESMO Spotlights 2014: Lung Cancer
- July 2012 ESMO Young Oncologists Committee: Update Lung Cancer ASCO 2012
- Reviewer of International Journals (Annals of Oncology, Journal of personalized medicine, World Journal of Surgical Oncology)
- Winner of several grants
- 1. ERA-NET on Translational Cancer Research (TRANSCAN) First Joint Transnational Call for Proposals (JTC 2011) on: "Validation of biomarkers for personalized cancer medicine: K-ras mutations and DNA repair function in NSCLC bio-RARE
- 2. Fondazione G. Berlucci per la Ricerca sul Cancro 2012: analisi delle tossicità oculari e dei polimorfismi correlati al trattamento con farmaci a target molecolare.
- 3. AIRC 2012: studio "LUME" lungo sopravvivenenti nel mesotelioma.
- 4. Fondazione G. Berlucci per la Ricerca sul Cancro 2014: Ricerca di nuovi fattori predittivi di risposta a erlotinib in pazienti con tumore del polmone non a piccole cellule senza mutazioni di EGFR
- 5. AIRC 2014: Targeting KRAS mutations in NSCLC through LKB1 co-vulnerability

Mother tongue German

Other language(s)

Self-assessment

European level (*)

Italian

English

French

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C1	advanced	C1	advanced	C 1	advanced	C1	advanced	C1	advanced
B2	intermediate	B2	intermediate	B2	intermediate	B2	intermediate	B2	intermediate
A2	beginner	A2	beginner	A2	beginner	A2	beginner	A2	beginner

(*) Common European Framework of Reference for Languages

Computer skills and competences

Microsoft Office

Driving licence

Driving licence B

Membership

European Society of Medical Oncology (ESMO)



Interests

Neoadjuvant and target therapy Immunotherapy Clinical trials

Publications

1. Otvos L Jr, **Haspinger E**, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J and Surmacz E. Design and Development of a Peptide-based Adiponectin Receptor Agonist for Cancer Treatment BMC Biotechnology, 11:90; 05 Oct 2011
2. Ferla R, **Haspinger E**, Surmacz E. Metformin Inhibits Leptin-induced Growth and Migration of Glioblastoma Cells., Cellular Biochemistry - JCB-11-0864
3. Agustoni F, Platania M, Vitali M, Zilembo N, **Haspinger E**, Sinno V, Gallucci R, de Braud F and Garassino MC. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev. 2014 Feb;40:197-203.
4. Gelsomino F, Agustoni F, Niger M, Valota M, **Haspinger ER**. EGFR tyrosine kinase inhibitor treatment in EGFR wild-type NSCLC patients: the never-ending story. Correspondence, J Clin Oncol. 2013 Sep 10;31:3291-3
5. Gelsomino F, Facchinetti, **Haspinger ER**, Garassino MC, de Braud F and Tiseo M. Targeting MET for the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 2014 Feb;89:284-99.
6. Pessi MA, Zilembo N, **Haspinger ER**, Molino L, Di Cosimo S, Garassino M and Ripamonti CI. Targeted therapy- induced diarrhea: a review of the literature. Crit Rev Oncol Hematol. 2013 Dec 5.
7. Pelosi G, **Haspinger ER**, Bimbatti M, Leone G, Paolini B, Fabbri A, Tamborini E, Perrone F, Testi MA, Garassino M, Maisonneuve P, de Braud F, Pilotti S, Pastorino U. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. Int J Surg Pathol. 2013 Dec 9.
8. Pusceddu S, Vitali M, **Haspinger E**, Tavecchio L, Giovannetti G, Bille' A, Concas L, Garassino M, Millione M, de Braud F and Buzzoni R. Update on therapeutic strategy in lung carcinoids. Accepted (JCT), in press.
9. **Haspinger ER**, Garassino MC, Torri V, Cinquini M, De Braud F, Gelsomino F. Do we really need another EGFR tyrosine Kinase Inhibitor in front line treatment for EGFR mutated NSCLC tumor patients? Correspondence, J Clin Oncol. 2014 Feb 3.
10. Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, **Haspinger ER**, Cortinovis D, Santo A, Banna G, Catino A, Giaj Levra M, Crinò L, de Marinis F, Cappuzzo F. Activity Of EGFR-HER-2 Dual Inhibitor Afatinib in EGFR mutant Lung Cancer Patients With Acquired Resistance To Reversible EGFR Tyrosine Kinase Inhibitors. Clinical Lung Cancer (accepted, in press)
11. Platania M, Valeri B, Marchianò A, Calareso G, Agustoni F, **Haspinger E**, Pusceddu S, Garassino MC, Gelsomino F, de Braud F. Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. Int J Colorectal Dis. 2014 Aug 21
12. Serpico D, Trama A, Haspinger E, Agustoni F, Botta L, Berardi R, Palmieri G, Zucali P, Gallucci R, Brogini M, Gatta G, Pastorino U, Pelosi G, De Braud F, Garassino MC. Available evidence and new biological perspectives on medical treatment for advanced thymic epithelial tumors. Ann Oncol. 2014 Nov 19
13. Haspinger ER, Agustoni F, Torri V, Gelsomino F, Platania M, Zilembo N, Gallucci R, Garassino MC, Cinquini M. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015 May;94(2):213-27. doi: 10.1016/j.critrevonc.2014.11.005. Epub 2014 Nov 22. Review
13. Dercle L, Ammari S, Bateson M, Durand PB, Haspinger E, Massard C, Jaudet C, Varga A, Deutsch E, Soria JC, Ferté C Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. Sci Rep. 2017 Aug 11;7(1):7952. doi: 10.1038/s41598-017-08310-5



Abstracts

1. Federico Cappuzzo, Marcello Tiseo, Rita Chiari, Lorenza Landi, Serena Ricciardi, Elisa Rossi, Domenico Galetta, Novello Silvia, Michele Milella, Armida D'Incecco, Eva Regina Haspinger, Diego Cortinovis, Antonio Santo, Giuseppe Banna, Facchinetti Francesco, Matteo Giaj Levra, Sabrina Vari, Lucio Crinò and Filippo De Marinis. Afatinib in EGFR mutant non-small-cell lung cancer patients with acquired resistance to reversible EGFR-TKIs. Aiom 2013
2. Marco Platania, Eva Regina Haspinger, Luca Roz, Giulia Bertolini, Elena Roz, Roberto Caserini, Marina Chiara Garassino, Ugo Pastorino, Gabriella Sozzi, Giuseppe Pelosi and Filippo de Braud. CD133 and EGFR status may represent markers able to predict early relapse and resistance in the treatment of locally advanced Non Small Cell Lung cancer patients. Aiom 2013
3. Eva Regina Haspinger, Francesco Agustoni, Francesco Gelsomino, Marina Chiara Garassino, Valter Torri and Michela Cinquini. Indirect comparisons of harm/benefit profile of EGFR tyrosine kinase inhibitors as first line treatment in EGFR mutated NSCLC patients: a systematic review and meta-analysis. IASLC 2013
4. L Botta, A Trama, M Garassino, M Tiseo, R Gallucci, G Gatta, G Pelosi, ER Haspinger. Malignant pleural mesothelioma long-term survivors: a study on population data base registries (LUME study). Aiom 2013
5. Haspinger ER, Platania M, Bertolini G, Caserini R, Landoni E, Roz E, Garassino MC, Zilembo N, Agustoni F, Vitali M, Serpico D, Gelsomino F, Giovannetti R, Billè A, Tavecchio L, Raimondii A, Pastorino u, de Braud F, Sozzi G and Roz L. Clinical relevance of CD133 positive cells in locally advanced non-small cell lung cancer. ESMO 2014
6. Bluthgen MV, Caramella C, Rosellini S, Leduc C, Facchinetti F, Haspinger E, Ferte C, Michiels S, Soria JC, Besse B. Texture Analysis as a Toll to Predict Molecular Signature in Advanced Non-Small Cell Lung Cancer (NSCLC). WCLC 2015
7. Dercle L, Ferte C, Jaudet C, Haspinger E, Sora JC, Ammari S. Evidence of a tumor signature in metastasis by quantitative texture analysis of CT – scan images. RSNA 2015.
8. Bluthgen MV, Caramella C, Faivre L, Rosellini S, Facchinetti F, Haspinger E, Ferte C, Ammari S, Michiels S, Soria JC, Besse B. Prognostic Value of Texture Analysis Advanced Non-Small Cell Lung Cancer (NSCLC). ESMO 2015
9. Haspinger ER, Rosellini S, Ammari S, Dercle L, Bluthgen MV, Besse B, Caramella C, Massard C, Lacroix L, De Baere T, Deschamps F, Michiels S, Soria JC, Ferte C. Radiomics to identify HER2 amplification or mutation in metastatic patients with solid tumors prospectively enrolled in MOSCATO – 01. ESMO 2015

Merano, 20.04.2020